Table 2 Description of breast cancer cases (n = 170) according to hormone receptor status and other tumor characteristics.

From: Reproductive factors and molecular subtypes of breast cancer among premenopausal women in Latin America: the PRECAMA study

Hormone receptor statusa

All cases

Col (%)

P53 positiveb

Row (%)

Ki-67 positivec

Row (%)

Age (years)d

ER+

122 (72%)

20 (16%)

88 (72%)

40.5 (30–45)

ER−

48 (28%)

24 (51%)

45 (96%)

38.5 (29–44)

PR+

123 (72%)

21 (17%)

88 (72%)

41.0 (30–45)

PR−

47(28%)

24 (51%)

45 (96%)

38 (29–44)

HER2+

32 (19%)

16 (50%)

28 (88%)

39.5 (28–44)

HER2−

138 (81%)

29 (21%)

105 (76%)

40 (30–45)

Triple-negative (ER−/PR−/HER2−)

36 (21%)

19 (53%)

35 (97%)

38 (30–45)

Of which Basal-like (TN + EGFR+ and/or CK5/6+)

33 (20%)

17 (51%)

32 (97%)

36 (30–45)

  1. aER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2. Overall score of ≥1% immunostained tumor cell nuclei was considered positive for ER+ or PR+; for HER2, was considered positive if membrane immunostaining 3+ and negative otherwise.
  2. bp53 positive when >10%; 1 participant with missing data.
  3. cKi-67 high when >14%.
  4. dMedian (10th percentile to 90th percentile); 1 participant with missing data.
Back to article page